NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)

Needs review: award amount not stated in source data

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is a funding call from National Institutes of Health that closes 05 April 2027. Funding: not stated in source data — see the official call. Eligibility: NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.

Funder: National Institutes of Health
Deadline: 05 Apr 2027 (172 days)
Amount: Not stated in source data — see call
Region / eligibility: United States
Career stage: established / PI, industry / SME
Fields: chemistry
Reference: PA-27-100
Official call: Grants.gov listing

Eligibility in plain language

NIH-style eligibility: US institutions only; non-US (foreign) organisations are not eligible to apply.

Who should apply

Synthetic, physical and analytical chemists — best fit for PIs and research groups or companies and SMEs.

Summary from source

The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.

Raw eligibility text

Only United States small business concerns (SBCs), as defined by the Small Business Administration (SBA)(sbir.gov/apply) are eligible to submit applications for this opportunity.Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Unfunded international collaborations or unfunded foreign components, as defined in the NIH Grants Policy Statement, may be allowed.